Lisa Musick

567 total citations
27 papers, 360 citations indexed

About

Lisa Musick is a scholar working on Pathology and Forensic Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Lisa Musick has authored 27 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pathology and Forensic Medicine, 15 papers in Oncology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Lisa Musick's work include Lymphoma Diagnosis and Treatment (21 papers), Chronic Lymphocytic Leukemia Research (11 papers) and CAR-T cell therapy research (11 papers). Lisa Musick is often cited by papers focused on Lymphoma Diagnosis and Treatment (21 papers), Chronic Lymphocytic Leukemia Research (11 papers) and CAR-T cell therapy research (11 papers). Lisa Musick collaborates with scholars based in United States, United Kingdom and Canada. Lisa Musick's co-authors include Jamie Hirata, Christopher C. Dvorak, Andrew McMillan, Janel Long-Boyle, Biljana Horn, Morton J. Cowan, Jason Law, Stephen Opat, Alex F. Herrera and Christopher R. Flowers and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Lisa Musick

26 papers receiving 358 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa Musick United States 9 202 195 73 60 55 27 360
Kenneth T. Luu United States 10 135 0.7× 93 0.5× 21 0.3× 71 1.2× 45 0.8× 18 357
Lionel Karlin France 13 253 1.3× 78 0.4× 308 4.2× 76 1.3× 47 0.9× 45 444
JN Ingle United States 11 270 1.3× 47 0.2× 51 0.7× 18 0.3× 58 1.1× 27 413
A. Groenewegen Netherlands 4 94 0.5× 28 0.1× 33 0.5× 38 0.6× 64 1.2× 6 311
Cindi Bedell United States 9 212 1.0× 36 0.2× 36 0.5× 40 0.7× 98 1.8× 14 401
Hyewon Lee South Korea 12 150 0.7× 62 0.3× 220 3.0× 88 1.5× 46 0.8× 38 424
M Masuda Japan 10 118 0.6× 42 0.2× 173 2.4× 72 1.2× 103 1.9× 22 382
M. Lamba United States 8 89 0.4× 44 0.2× 76 1.0× 29 0.5× 138 2.5× 17 356
Mardiah Suci Hardianti Indonesia 10 99 0.5× 65 0.3× 18 0.2× 43 0.7× 48 0.9× 55 315
Pallawi Torka United States 11 120 0.6× 129 0.7× 35 0.5× 77 1.3× 59 1.1× 67 313

Countries citing papers authored by Lisa Musick

Since Specialization
Citations

This map shows the geographic impact of Lisa Musick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Musick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Musick more than expected).

Fields of papers citing papers by Lisa Musick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Musick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Musick. The network helps show where Lisa Musick may publish in the future.

Co-authorship network of co-authors of Lisa Musick

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Musick. A scholar is included among the top collaborators of Lisa Musick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Musick. Lisa Musick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Xiaoyong, Tarec Christoffer El‐Galaly, Lale Kostakoglu, et al.. (2024). Automated Lugano Metabolic Response Assessment in 18 F-Fluorodeoxyglucose–Avid Non-Hodgkin Lymphoma With Deep Learning on 18 F-Fluorodeoxyglucose–Positron Emission Tomography. Journal of Clinical Oncology. 42(25). 2966–2977. 6 indexed citations
2.
3.
Song, Yuqin, Qingyuan Zhang, Liling Zhang, et al.. (2024). Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients. Journal of Cancer Research and Therapeutics. 20(7). 2133–2140. 1 indexed citations
4.
Abrisqueta, Pau, Eva González‐Barca, Carlos Panizo, et al.. (2024). Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. The Lancet Haematology. 11(2). e136–e146. 7 indexed citations
5.
Yuen, Sam, Tycel Phillips, Rajat Bannerji, et al.. (2024). Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma. American Journal of Hematology. 99(7). 1281–1289. 4 indexed citations
6.
Flowers, Christopher R., Matthew J. Matasar, Alex F. Herrera, et al.. (2023). Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study. Haematologica. 109(4). 1194–1205. 4 indexed citations
7.
Diefenbach, Catherine, Brad S. Kahl, Andrew McMillan, et al.. (2022). A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update. Blood. 140(Supplement 1). 2286–2288. 1 indexed citations
8.
Sehn, Laurie H., Mark Hertzberg, Stephen Opat, et al.. (2021). Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Advances. 6(2). 533–543. 107 indexed citations
9.
Diefenbach, Catherine, Pau Abrisqueta, Eva González‐Barca, et al.. (2021). Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.. Journal of Clinical Oncology. 39(15_suppl). 7512–7512. 8 indexed citations
10.
Matasar, Matthew J., Corinne Haïoun, Juan‐Manuel Sancho, et al.. (2021). POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood. 138(Supplement 1). 3568–3568. 4 indexed citations
11.
Bannerji, Rajat, Sam Yuen, Tycel Phillips, et al.. (2021). POLATUZUMAB VEDOTIN + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL. Hematological Oncology. 39(S2). 3 indexed citations
12.
Diefenbach, Catherine, Brad S. Kahl, Andrew McMillan, et al.. (2021). Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. The Lancet Haematology. 8(12). e891–e901. 20 indexed citations
13.
14.
Gritti, Giuseppe, Paula Marlton, Tycel Phillips, et al.. (2020). Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study. Blood. 136(Supplement 1). 45–47. 16 indexed citations
15.
Diefenbach, Catherine, Brad S. Kahl, Andrew McMillan, et al.. (2019). Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a phase Ib/II trial.. Journal of Clinical Oncology. 37(15_suppl). 7505–7505. 5 indexed citations
16.
17.
Diefenbach, Catherine, Brad S. Kahl, Andrew McMillan, et al.. (2019). POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE IB/II INTERIM ANALYSIS. Hematological Oncology. 37(S2). 175–176. 3 indexed citations
18.
Levy, Emily R., Lisa Musick, Matt S. Zinter, et al.. (2015). Safe and Effective Prophylaxis with Bimonthly Intravenous Pentamidine in the Pediatric Hematopoietic Stem Cell Transplant Population. The Pediatric Infectious Disease Journal. 35(2). 135–141. 9 indexed citations
19.
Long-Boyle, Janel, Rada Savic, Imke H. Bartelink, et al.. (2014). Population Pharmacokinetics of Busulfan in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplant. Therapeutic Drug Monitoring. 37(2). 236–245. 66 indexed citations
20.
Law, Jason, Morton J. Cowan, Christopher C. Dvorak, et al.. (2012). Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-Host Disease without Delaying Immune Reconstitution. Biology of Blood and Marrow Transplantation. 18(11). 1656–1663. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth T. Luu Breakdown of academic impact, for papers by Lionel Karlin Breakdown of academic impact, for papers by JN Ingle Breakdown of academic impact, for papers by A. Groenewegen Breakdown of academic impact, for papers by Cindi Bedell Breakdown of academic impact, for papers by Hyewon Lee Breakdown of academic impact, for papers by M Masuda Breakdown of academic impact, for papers by M. Lamba Breakdown of academic impact, for papers by Mardiah Suci Hardianti Breakdown of academic impact, for papers by Pallawi Torka
Rankless by CCL
2026